Docon Sells 9.9% Stake in Thyrocare for Rs 986 Crore

Docon Technologies, a key promoter of Thyrocare Technologies Ltd, has divested a 9.9% stake in the diagnostics company, securing Rs 986 crore through a combination of bulk and block deals. The transaction took place on Thursday across the National Stock Exchange (NSE) and the Bombay Stock Exchange (BSE), involving a total of 1,57,69,696 equity shares.

Transaction Details and Market Reaction

The shares were sold within a price range of Rs 624 to Rs 631.71 each. Following this sale, Docon's ownership in Thyrocare decreased from 60.92% to 51.02%. On the following day, Thyrocare's stock saw an uptick, gaining nearly 3% on the NSE to close at Rs 621.95, and over 2% on the BSE, closing at Rs 622.

Institutional Participation

The sale attracted significant interest from institutional investors and insurance companies. Notable buyers through block deals included HSBC Mutual Fund, DSP Mutual Fund, ICICI Prudential Mutual Fund, Aditya Birla Sun Life Mutual Fund, WhiteOak Capital Mutual Fund, and ITI Mutual Fund. Insurance firms such as Kotak Mahindra Life Insurance Company and Tata AIA Life Insurance were also participants, alongside global entities like Morgan Stanley, Citigroup Global Markets, HBM Healthcare Investments (Cayman), and the Kuwait Investment Authority.

Historical Context and Future Implications

This recent transaction follows a similar move by Docon in October of the previous year, when it sold a 10% stake in Thyrocare for Rs 667 crore. The consistent reduction in holdings suggests a strategic shift by Docon, though the company retains a majority stake. The influx of capital and interest from diverse investors could potentially lead to further developments in Thyrocare’s operations and market strategies.